denosumab – Prolia

What You Need to Know About Xgeva or Denosumab

Xgeva, also known as denosumab, is an injectable medication (injected once a month subcutaneously under the skin in the doctor’s office) that is used to prevent bone fractures and spinal cord compression caused by bone metastases in breast and prostate cancer survivors. Solid tumors in the bone, which is a common site for individuals with breast and prostate cancer, can cause significant complications. Potential complications of these tumors include bone fractures and spinal cord compression that could lead to the need for radiation treatment or surgery to the involved bones as well as possible paralysis. Xgeva is used to prevent [...]

Using Denosumab (Xgeva) To Combat Skeletal Complications in Prostate Cancer

Xgeva is a monoclonal antibody that inactivates RANKL, a protein that enhances osteoclast activity and survival. By inhibiting RANKL, Xgeva prevents skeletal-related events in men with bone metastasis from prostate cancer. Under no circumstances should a man who also has multiple myeloma use Xgeva. There have been studies that compared Xgeva to zolendronic acid (Zometa). They concluded that the men using Xgeva had a longer period of time before they developed a skeletal-related event (bone metastases or fracture) then those men who received zolendronic acid. Despite this, overall survival was not improved. When receiving Xgeva you should have normal calcium [...]

Will the FDA Approve Xgeva – It is “Up In The Air”

Prior to the formal review, the FDA has raised questions about the ultimate approval of Amgen’s Xgeva (denosumab) for men with metastatic, advanced prostate cancer who have not yet developed metastasized to the bone. Xgeva has been shown to delay tumors spreading to bones, but it does not extend life, the holy grail of the FDA. The FDA will be holding on February 8 an advisory panel that will meet to recommend whether to expand Xgeva’s use (currently it is approved for men who have developed bone metastasizes) to include men with advanced prostate cancer who have not yet developed [...]

Osteonecrosis Of The Jaw While Taking Zometa & Xgeva

The use of denosumab (Xgeva) as an alternative to the more commonly prescribed zoledronic acid (Zometa) to slow down the development of bone metastases in men with advanced prostate cancer is becoming more common. The most common concern for men taking Zometa and now Xgeva has been osteonecrosis of the jaw. Osteonecrosis of the jaw is basically severe bone disease which is associated with bisphosphonate therapy (Zometa and now Xgeva). One of the more common questions asked by many people is if osteonecrosis of the jaw is more or less common in men taking Zometa or Xgeva? The answer is [...]